Clinical Trial Update: Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... [Phase 1]

View source ↗

Summary

Phase I trial of pexidartinib (TURALIO) in children and young adults with refractory leukemias and solid tumors including NF1-associated plexiform neurofibromas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia Lymphoma
• Acute Promyelocytic Leukemia
• Neurofibromatosis Type
• Plexiform Neurofibroma
• Sarcoma
• Tenosynovial Giant Cell Tumor

Drugs mentioned

• TURALIO (pexidartinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | Status: RECRUITING